Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ

Activist investor Jana Partners is urging $10 billion medical-device maker Cooper Cos. to replace CEO Albert White, appoint a new board chair and explore strategic alternatives, including a sale of its contact-lens business and potential divestiture of fertility and medical-device assets. Jana cited chronic underperformance, inventory management and capital-spending shortcomings after Cooper shares fell about 16% over the past year and 28% since Jana's earlier strategic push. A potential proxy fight is possible, with the director nomination window closing in early January.

Analysis

The investable issue is whether the activist can force a separation that rerates COO from a diversified medtech multiple to a higher-quality recurring-consumables valuation. CooperVision's defensible channel position and repeat-purchase lens mix are likely worth more as a stand-alone asset than within a conglomerate discount, while CooperSurgical's fertility exposure has a distinct growth, reimbursement, and capital-intensity profile. A sale of the lens business to BLCO would face meaningful antitrust review in major lens categories, making a tax-efficient separation or minority carve-out more plausible than a near-term full merger.

Near term, activism creates an event floor for COO, but the catalyst path depends on board engagement and whether director nominations are still procedurally available; this must be verified against the current advance-notice window. Over 1-3 months, a credible independent-chair appointment, retention of advisers, or segment-level margin/ROIC disclosures would support multiple expansion even without a transaction. The key downside is that inventory normalization and sales-force investment may depress earnings conversion for several quarters, allowing management to argue that operational execution—not structure—is the appropriate remedy.

Consensus may overestimate BLCO's ability to finance a transformational acquisition. BLCO would gain scale and purchasing leverage, but funding a deal with leverage or equity could dilute the economics and invite regulatory remedies; BLCO is therefore a better read-through beneficiary than a clean takeover target. The structural winner from a COO separation could instead be strategic acquirers with balance-sheet capacity, while standalone CooperSurgical could attract sponsors only if its cash generation can support leverage without constraining R&D and commercial investment.

Key Decisions for Investors

• Initiate a 1-3 month long COO / short IHI pair at roughly market-neutral beta after confirming the activist's stake size and nomination rights. Target 10-15% relative upside from governance and strategic-review optionality; exit if COO rejects engagement and provides no segment-margin, ROIC, or capital-allocation changes by the next earnings call.
• Do not underwrite a BLCO acquisition premium. Maintain BLCO as a catalyst watch only; consider a tactical long only if BLCO discloses financing capacity and regulatory strategy, since a debt-funded bid or substantial divestiture package would likely pressure BLCO's equity.
• Buy COO call spreads expiring just after the next earnings release only if implied volatility remains below the stock's post-activism realized-volatility range. A limited-risk upside structure is preferable to outright stock for an event-driven position; abandon if options already price a double-digit move or a transaction probability inconsistent with antitrust risk.
• Monitor COO inventory days, gross-margin progression, operating cash conversion, and sales-force productivity over the next two quarters. Improvement in these metrics would strengthen the standalone rerating case; deteriorating inventory and another guidance reset would falsify the thesis and shift the risk/reward toward a short COO versus diversified medtech.